Pulmonology

Molgramostim shows significant lung function and quality of life improvements in 48-week study for aPAP

Savara announced positive data from its Phase 3 IMPALA-2 trial of molgramostim, a nebulizer solution for treating autoimmune pulmonary alveolar proteinosis (aPAP). The IMPALA-2 trial showed promising results for molgramostim in treating lung conditions. At Week 24, the primary goal of improving lung function (measured by DLCO%) was met, and...